Skip to main navigation menu Skip to main content Skip to site footer

Vol. 13 No. 5 (2026)
International Multidisciplinary Journal for Research & Development

Articles

ANALYSIS OF THE RELEVANCE OF MEASURES TO IMPROVE PHARMACOTHERAPY FOR KIDNEY DISEASES

Published 2026-05-26

  • Sokhib Zamon o'g'li Rashidov
    • ,
  • Davronbek Salim oʻgʻli A'zamov
    • ,
  • Zukhriddin Alisher oʻgʻli Oʻrishboev

Sokhib Zamon o'g'li Rashidov
Department of the pharmacology of the Tashkent state medical university

Davronbek Salim oʻgʻli A'zamov
Tashkent state medical university

Zukhriddin Alisher oʻgʻli Oʻrishboev
Tashkent state medical university

Abstract

One of the main objectives of treating chronic kidney disease (CKD) is to slow the illness's progression and lower the chance of death. Until recently, new medication classes to supplement renin-angiotensin-aldosterone system (RAAS) inhibitors as the standard of care hardly achieved their main goals. In order to determine what new information adds to the therapy landscape, this systematic literature analysis examined therapies assessed in CKD patients since 1990. The coexistence of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) significantly increases cardiovascular morbidity and mortality by two to three times compared to patients without CKD. CKD is a major public health concern that is sweeping the country. The care of chronic kidney disease (CKD) includes both pharmaceutical and non-pharmacological strategies, such as dietary salt reduction and lifestyle changes to lower blood pressure. Renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and mineralocorticoid receptor antagonists (MRAs) are the four main pillars of current pharmacological management, all of which have demonstrated cardiovascular and renoprotective benefits. One of the things causing kidney damage to worsen is an incomplete block of aldosterone activity, which is still a problem. Vicadrostat and other aldosterone synthase inhibitors (ASIs) may open up new possibilities for selectively blocking aldosterone synthesis while maintaining cortisol production. Reductions in albuminuria and the possibility of renal protection have been demonstrated in early-phase trials. Is it possible for ASIs to become a fifth pillar in the management of CKD and slow its progression?

Keywords

Sglt2 inhibitors, aldosterone, mineralocorticoid receptor antagonists, chronic renal disease, ace inhibitors, renal protection.

PDF

References

  1. Garcia Sanchez JJ, Thompson J, Scott DA, Evans R, Rao N, Sörstadius E, James G, Nolan S, Wittbrodt ET, Abdul Sultan A, Stefansson BV, Jackson D, Abrams KR. Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. Adv Ther. 2022 Jan;39(1):193-220. doi: 10.1007/s12325-021-02006-z.
  2. Treihaft AM, Parikh MA, Jackson KA, Frishman WH, Peterson SJ. New Therapies for the Management of Chronic Kidney Disease. Cureus. 2025 Apr 7;17(4):e81824. doi: 10.7759/cureus.81824.
  3. Baxdrostat: an aldosterone synthase inhibitor for the treatment of systemic hypertension. Dey S, Frishman WH, Aronow WS. Cardiol Rev. 2023;0:0. doi: 10.1097/CRD.0000000000000595.
  4. Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.
  5. Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761
  6. Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670
  7. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01
  8. Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07
  9. Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06
  10. Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863
  11. Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820
  12. Sokhib Rashidov Zamon oʻgʻli, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o‘g‘li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856
  13. Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434
  14. Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN : 2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577
  15. Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.
  16. Sokhib Rashidov Zamon oʻgʻli, Nilufar Ergasheva Agʼzamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065
  17. Sokhib Rashidov Zamon oʻgʻli, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Poʻlatjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141
  18. Sokhib Rashidov Zamon oʻgʻli, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania. Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142
  19. Sokhib Rashidov Zamon oʻgʻli, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.
  20. Sokhib Rashidov Zamon oʻgʻli, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qoʻshbekova Roʻzimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857
  21. SGLT2 inhibitors in diabetic kidney disease. Zoungas S, de Boer IH. Clin J Am Soc Nephrol. 2021;16:631–633. doi: 10.2215/CJN.18881220.
  22. Dapagliflozin in patients with chronic kidney disease. Heerspink HJ, Stefánsson BV, Correa-Rotter R, et al. N Engl J Med. 2020;383:1436–1446. doi: 10.1056/NEJMoa2024816.
  23. GLP-1 receptor agonists in diabetic kidney disease: from physiology to clinical outcomes. Rojano Toimil A, Ciudin A. J Clin Med. 2021;10:3955. doi: 10.3390/jcm10173955.
  24. Clinical utility of osilodrostat in Cushing’s disease: review of currently available literature. Perosevic M, Tritos NA. Drug Des Devel Ther. 2023;17:1303–1312. doi: 10.2147/DDDT.S315359.
  25. Emerging therapies for treatment-resistant hypertension: a review of lorundrostat and related selective aldosterone synthase inhibitors. Feldman JM, Frishman WH, Aronow WS. Cardiol Rev. 2024;0:0. doi: 10.1097/CRD.0000000000000665.
  26. Baxdrostat: an aldosterone synthase inhibitor for the treatment of systemic hypertension. Dey S, Frishman WH, Aronow WS. Cardiol Rev. 2023;0:0. doi: 10.1097/CRD.0000000000000595.

Downloads

Download data is not yet available.